Drug-induced lupus erythematosus

Clinics in Dermatology

Volumn 16, Issue 3, 1998, Pages 367-377

  Pramatarov, Kyrill D ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTINUCLEAR ANTIBODY; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CELL NUCLEUS ANTIGEN; CHLORPROMAZINE; CLOBAZAM; DNA ANTIBODY; ELASTASE; HLA ANTIGEN; HYDRALAZINE; HYDROXYUREA; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; ISONIAZID; METHYLDOPA; MINOCYCLINE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENICILLAMINE; PROCAINAMIDE; QUINIDINE; RECOMBINANT ALPHA INTERFERON; SALAZOSULFAPYRIDINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALPROIC ACID;

CLINICAL FEATURE; DISEASE COURSE; DRUG INDUCED DISEASE; HEREDITY; HUMAN; HYPERTENSION; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032077259     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(98)00007-8     Document Type: Article

References (112)

1. 1. Hess E. Drug-related lupus. N Engl J Med 1988;318: 1460-2.
2. 2. Fritzler M. Drugs recently associated with lupus syndromes. Lupus 1994;3:455-9.
3. 3. Huffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph 1945;51:190-2.
4. 4. Morrow JD, Schroeder HA, Perry HM. Studies on the control of hypertension by Hyphex: II. Toxic reactions and side effects. Circulation 1953;8:829-39.
5. 5. Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med 1962;267:1357-8.
6. 6. Hofstra A. Metabolism of hydralazine: Relevance to drug-induced lupus. Drug Metab Rev 1994;26:485-505.
7. 7. Perry HM. Possible mechanisms of the hydralazine-related lupus-like syndrome. Arthritis Reuma 1981; 24: 1093-1104.
8. 8. Hildreth EA, Biro CE, McCreary TA. Persistence of the "hydralazine syndrome": A follow-up study of eleven cases. JAMA 1960;173:657-60.
9. 9. Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine-induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility. Lancet 1980;24:1107.
10. 10. Torffvit O, Thysell H, Naessberger L. Occurrence of autoantibodies directed against myeloperoxidase and elastase in patients treated with hydralazine and presenting with glomerulonephritis. Hum Exp Toxicol 1994; 13:563-7.
11. 11. Naessberger L, Sjoholm AG, Jonsson H, et al. Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 1990;81:380-3.
12. 12. Nassberger L, Hultquist R, Sturfelt G. Occurrence of anti-lactoferrin antibodies in patients with systemic lupus erythematosus, hydralazine-induced lupus, and rheumatoid arthritis. Scand J Rheumatol 1994;23:206-10.
13. 13. Peterson LL. Hydralazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984;10:379-84.
14. 14. Schattner A, Stoeger Z, Geltner D. Effect of acute cytomegalovirus infection on drug-induced SLE. Postgrad Med J 1994;70:738-40.
15. 15. Lee SL, Chase PH. Drug-induced systemic lupus erythematosus: A critical review. Semin Arthritis Rheum 1975;5:83-103.
16. 16. Uetrecht JP. Mechanism of drug-induced lupus. Chem Res Toxicol 1988;1:134-43.
17. 17. Rubin RL, Burlingame RW, Arnott JE, et al. IgG but not other classes of anti-(H2A-H2B)-DNA is an early sign of procainamide-induced lupus. J Immunol 1995;154:2483-93.
18. 18. Muramatsu M, Nakajima M, Mori M, et al. A case of primary antiphospholipid antibody syndrome associated with procainamide-induced systemic lupus erythematosus. Nippon Naika Gakkai Zasshi 1995; 84:1736-8.
19. 19. Baker H, Moore-Robinson M. Procainamide-induced systemic lupus erythematosus. Br J Dermatol 1970;83: 320-1.
20. 20. Dubois EL. Procainamide induction of a systemic lupus erythematosus-like syndrome. Medicine 1969;48:217-28.
21. 21. Blomgren SE, Vaughan GH. The immunogenecity of photo-oxidized DNA and of the product of DNA and procainamide-induced lupus. Arthritis Rheum 1968;11: 470.
22. 22. Koffler D, Carr R, Agnello V, et al. Antibodies to polynucleotides in human sera: Antigenic specificity and relation to disease. J Exp Med 1971;134:294-312.
23. 23. Perry HM, Tane M, Carmody S, et al. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med 1970;76:114-25.
24. 24. Sherman JD, Love DE, Harrington JF. Anemia, positive lupus and rheumatoid factors with methyldopa. Arch Intern Med 1967;120:321-6.
25. 25. Sakurai Y, Kurihara R, Takeuchi M, et al. A case of SLE-like syndrome and severe hemolytic anemia caused by methyldopa. Nippon Naika Gakkai Zasshi 1995;84: 2069-71.
26. 26. Kendall MJ, Hawkins CF. Quinidine-induced systemic lupus erythematosus. Postgrad Med J 1970;46:729-31.
27. 27. Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Arthritis Rheum 1995;24:315-22.
28. 28. Laversuch CJ, Collins DA, Charles PJ, et al. Sulfasalazine-induced autoimmune abnormalities in patients with rheumatic disease. Br J Rheumatol 1995;34:435-39.
29. 29. Veale DJ, Ho M, Morley KD. Sulfasalazine-induced lupus in psoriatic arthritis. Br J Rheumatol 1995;34:383-84.
30. 30. Walker EM, Carty JE. Sulphasalazine-induced systemic lupus erythematosus in a patient with erosive arthritis. Br J Rheumatol 1994;33:175-6.
31. 31. Khattak FH, Morris IM, Mattingly PC. Sulphasalazine-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. Br J Rheumatol 1996;35:104.
32. 32. Bray VJ, Sterling GW, Schultz KT, et al. Antihistone antibody profile in sulfasalazine-induced lupus. J Rheumatol 1994;21:2157-8.
33. 33. Mielke H, Wildhagen K, Mau W, et al. Follow-up of patients with double-stranded DNA antibodies induced by sulfasalazine during the treatment of inflammatory rheumatic diseases. Rheumatology 1993;22:229-301.
34. 34. Caulier M, Dromer C, Andrieu V, et al. Sulfasalazine-induced lupus in rheumatoid arthritis. J Rheumatol 1994; 21:750-1.
35. 35. Trost H, Boni A. Medikamentos induzierter systemischer lupus erythematodes. Z Rheumatol 1980;39:309-13.
36. 36. Quietzsch J, Baumgarten C. Familiare primar generalisierte epilepsie und medikamentos ausgeloster systemischer lupus erythematodes. Z Rheumatol 1992;31:65-77.
37. 37. De Giorgio CM, Rabinovicz AL, Olivas RD. Chlorpromazin-induced antinuclear antibodies and systemic lupus erythematosus-like syndrome. Epilepsia 1991;32:128-9.
38. 38. Schmidt M, Welcker M, Grail W, et al. Carmazepine-induced systemic lupus erythematosus. Br J Psychiatry 1992;161:560-1.
39. 39. Alballa S, Fritzler M, Davis P. A case of drug-induced lupus due to carbamezepin. J Rheumatol 1987;14:599-600.
40. 40. Bateman DE. Carbamezepin-induced systemic lupus erythematosus: Case report. Br Med J 1985;291:632-3.
41. 41. Dvory VE, Just I, Korczyn AD. Carbamezepin-induced systemic lupus erythematosus. Clin Neuropharmacol 1989;12:115-8.
42. 42. Ansell BM. Drug-induced systemic lupus erythematosus in a nine-year old boy. Lupus 1992;2:193-4.
43. 43. Wring ES, Aspet SP. Observations on the use of propylthiouracil in hyperthyroidism with especial reference to long term treatment. John's Hopkins Med 1952;90:201-27.
44. 44. Sato-Matsumura KC, Koizumi H, Mazumura T, et al. Lupus erythematosus-like syndrome induced by thiamazole and propylthiouracil. J Dermatol (Tokyo) 1994;21: 501-7.
45. 45. Kawachi Y, Nukaga H, Hoshino N, et al. ANCA-associated vasculitis and lupus-like syndrome caused by methymazole. Clin Exp Dermatol 1995;20:345-7.
46. 46. Chalmers A, Thompson D, Stein HE, et al. Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis. Ann Intern Med 1982;97:659-663.
47. 47. Tsankov N, Lazarova A, Vasileva S, et al. Lupus erythematosus-like eruption due to D-penicillamine in progressive systemic sclerosis. Int J Dermatol 1990;29:571-574.
48. 48. Walshe J. Penicillamine and the SLE syndrome. J Rheumatol 1981;8(Suppl):155-60.
49. 49. Cahn MF, Peltier AP, Degraeve B, et al. Connectivites successive: (sclerodermies puis lupus) etude clinique et biologique de 4 observations. Ann Med Interne (Paris) 1977;128:1-8.
50. 50. Kirby JD, Dieppe PA, Huskisson EG, et al. D-Penicillamine and immune complex deposition. Ann Rheum Dis 1979;38:344-6.
51. 51. Enzenauer RJ, West SG, Rubin RL. D-Penicillamine-induced lupus erythematosus. Arthritis Rheum 1990;33: 1382-3.
52. 52. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorthiazide therapy. Ann Intern Med 1983;103:49-51.
53. 53. Berbis Ph, Vernay-Vaisse Ch, Privat J. Lupus cutane subaigu observe au cours d'un traitement par diuretiques thiazidique. Ann Dermatol Venereol 1986; 113: 1245-8.
54. 54. Darken M, McBurney E. Subacute cutaneous-like drug eruption due to combination diuretic hydrochlorthiazide and triamterene. J Am Acad Dermatol 1988;18:38-42.
55. 55. Goodrich A, Kohn S. Hydrochlorthiazide-induced lupus erythematosus: A new variant? J Am Acad Dermatol 1993;28:1001-2.
56. 56. Wollenberg A, Meurer M. Thiazid-diuretika-induzierter subakut-kutaner lupus erythematodes. Hautartz 1991;42: 709-12.
57. 57. Brown CW, Deng JS. Thiazide diuretics induce lupus-like adverse reaction. J Clin Toxicol 1995;33:729-33.
58. 58. Zamber RW, Starkebaum G, Rubin RL, et al. Drug-induced systemic lupus erythematosus due to ophthalmic timolol. J Rheumatol 1992;19:977-9.
59. 59. Castleman L, Mandelbaum RA. Gold poisoning and disseminate lupus erythematosus. Am Pract 1950;1:561-8.
60. 60. Walsh JR, Zimmerman JH. The demonstration of the LE phenomenon in patients with penicillin hypersensitivity. Blood 1953;8:65-71.
61. 61. Popkhristov P, Kapnilov S. Streptomycin as a factor producing and aggravating lupus erythematosus. Vestn Dermatol Venerol (Moscow) 1960;34:10-5.
62. 62. Domz CA, McNamara DH, Holzapfel HF. Tetracycline provocation in LE. Ann Intern Med 1959;50:1217-26.
63. 63. Farid N, Anderson J. SLE-like reaction to phenylbutazone therapy. Lancet 1971;1:1022-3.
64. 64. Kay DR, Bole GG, Ledger WJ. The use of oral contraceptives and the occurrence of antinuclear antibodies and LE cells in women with early rheumatic disease. Arthritis Rheum 1969;12:306.
65. 65. Alexander S. Lupus erythematosus in two patients after griseofulvin treatment of Trichophyton rubrum infection. Br J Dermatol 1962;74:72-4.
66. 66. Bonilla-Felix M, Verani R, Vanasse LG, et al. Nephrotic syndrome related to systemic lupus erythematosus after griseofulvin therapy. Pediatr Nephrol 1995;9:478-9.
67. 67. Allston LL. Lupus-like syndrome from minocycline. Schoch Lett 1984;34:29.
68. 68. Matsuura T, Shimitzu Y, Fujimoto H, et al. Minocycline-related lupus. Lancet 1992;340:1353.
69. 69. Byrne PA, Williams BD, Pritchard MH. Minocycline-related lupus. Br J Rheumatol 1994;33:674-6.
70. 70. Quilty B, McHugh N. Lupus-like syndrome associated with the use of minocycline (letter). Br J Rheumatol 1994;33:1197-8.
71. 71. Inoue CN, Kondo Y, Suwabe N, et al. Minocycline-related lupus in childhood (letter). Eur J Pediatr 1994;153: 540.
72. 72. Gordon PM, White MI, Herriot R, et al. Minocyclineassociated lupus erythematosus. Br J Dermatol 1955;132: 120-1.
73. 73. Gough A, Chapman S, Wagstaff K, et al. Minocycline-induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br Med J 1996;312:169-72.
74. 74. Golstein Ph, Deviere J, Cremer M. Acute hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997;92:143-6.
75. 75. Bleck TP, Smith MC. Possible induction of systemic lupus erythematosus by valproate. Epilepsia 1990; 31:343-5.
76. 76. Asconape J, Manning K, Lancman M. Systemic lupus erythematosus associated with use of valproate. Epilepsia 1994;35:162-3.
77. 77. Crawson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. N Engl J Med 1995;21:14-29.
78. 78. Crawson AN, Magro CM. Subacute cutaneous lupus erythematosus arising in the setting of calcium-channel blockers therapy. Human Pathol 1997;28:67-71.
79. 79. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207-10.
80. 80. Schilling PJ, Kurzrock R, Kantarjian H, et al. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991; 68:1336-7.
81. 81. Wande UB, Nagel-Hiemke M, May D, et al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992;65:70-4.
82. 82. Sanchez-Roman J, Castillo-Palma MJ, Garcia-Diatz E, et al. Systemic lupus erythematosus induced by recombinant alpha interferon treatment (letter). Med Clin (Barc) 1994;102:198.
83. 83. Massaroti LM, Lui NY, Mier J, et al. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy. Am J Med 1992;92:693-7.
84. 84. Sieber C, Grimm E, Follath F. Captopril and systemic lupus erythematosus syndrome. Br Med J 1990;310:669.
85. 85. Fernandez-Diaz ML, Herant P, Suarez-Marrero NC, et al. Subacute cutaneous lupus erythematosus associated with cilazapril (captopril) Lancet 1995;345:398.
86. 86. Mamoux V, Dumont C. Lupus erythemateux dissemine et vaccination contre hepatite B. Arch Pediatr 1994;3:307.
87. 87. Layton AM, Cotterill JA, Tomlisson LW. Hydroxyurea-induced lupus erythematosus. Br J Dermatol 1994;130: 687-8.
88. 88. Caramashi P, Biasi D, Carletto A, et al. Clobazam-induced lupus erythematosus (letter). Clin Rheumatol 1995;14:116.
89. 89. Wickert WA, Campbell NR, Martin L. Acute severe adverse clozapine reaction resembling systemic lupus erythematosus (letter). Postgrad Med J 1994;70:940-1.
90. 90. Mysler E, Paget SA, Kimberly R. Ciprofloxacin reactions mimicking lupus flares. Arthritis Rheum 1994;37:1112-3.
91. 91. Gelfand MS, Yunus F, White FL. Bone marrow granulomas, fever, pancytopenia and lupus-like syndrome due to tocainide. South Med J 1994;87:839-41.
92. 92. Heilmann G, Hien P. Clonidine therapy as cause of lupus erythematosus (letter). Dtsch Med Wochenschr 1994;119: 858-9.
93. 93. Federmann M, Morell B, Graetz G, et al. Hypersensitivity to molybdenum as a possible trigger of ANA-negative systemic lupus erythematosus. Ann Rheum Dis 1994;53: 403-5.
94. 94. Kale SA. Drug-induced systemic lupus erythematosus: Differentiating it from the real thing. Postgrad Med 1985; 77:231-5.
95. 95. Price EJ, Venables PJ. Drug-induced lupus. Drug Saf 1995;12:283-90.
96. 96. Berova N, Pramatarov K, Tsankov N. Differential diagnosis of lupus erythematodes medicamentosus. Dermatol Venereol (Sofia) 1990;2:48-51.
97. 97. Rubin RL, Bell SA, Burlingame RW. Autoantibodies associated with lupus induced by diverse drugs target similar epitope in the (H2A-H2B)-DNA complex. J Clin Invest 1992;90:165-73.
98. 98. Burlingame RW, Rubin RL. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991;85:680-90.
99. 99. Vivino FB, Schumacher HR. Synovial fluid characteristics and the lupus erythematosus cell phenomenon in drug-induced lupus. Arthritis Rheum 1989;32:560-7.
100. 100. Fritzler MJ, Tan EM. Antibodies to histones in drug-induced and idiopathic lupus erythematosus. J Clin Invest 1978;62:560-7.
101. 101. Alarcon-Segovia D. Drug-induced lupus syndromes. Mayo Clin Proc 1969;44:664-81.
102. 102. Alarcon-Segovia D, Worthington JW, Ward LE, et al. Lupus diathesis and the hydralazine syndrome. N Engl J Med 1965;272:462-6.
103. 103. Sakane T, Tsuchida T. Association of HLA with SLE. Clin Immunol Hihon Rinsyo 1990;48(Suppl):597-607.
104. 104. Uetrecht JP, Woosley RL. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet 1981;6:118-34.
105. 105. von Schmiedeberg SH, Goebel C, Gleichmann E, et al. Neutrophils and drug metabolism. Science 1995;268: 585.
106. 106. Jiang X, Khursigara G, Rubin R. Transformation of lupus-inducing drugs to cytotoxic products by activate neutrophils. Science 1994;266:810-3.
107. 107. Sim E, Gill EW, Sim RB. Drugs that induce systemic lupus erythematosus inhibit complement C4. Lancet 1984;2:422-4.
108. 108. Hill ME, Gordon C, Situnayake RD, et al. Sulfasalazine-induced seizures and dysphasia. J Rheumatol 1994;21: 748-9.
109. 109. Burry JN. Lipstick lupus erythematosus. N Engl J Med 1969;281:620.
110. 110. Sanchez-Guerrero J, Karlson EW, Colditz GA, et al. Hair dye use and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1996;39:657-62.
111. 111. Beer KR, Lorincz AL, Medenica MM, et al. Insecticide-induced lupus erythematosus. Int J Dermatol 1994;33: 860-2.
112. 112. Hess EV. Drug and environmental lupus syndromes (editorial). Lupus 1994;3:441-2.